New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in some patients at low fracture risk
July 2013
New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in some patients at low fracture risk.
This is a case of labeling catching up with the evidence.
Bisphosphonates persist in the bones for years. So 3 to 5 years is enough for many patients...because benefits seem to last even after treatment is stopped.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote